Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial.

doi:10.1158/1078-0432.CCR-22-0371

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2022

Barlesi Fabrice, Tomasini Pascale, Karimi Maryam, Michiels Stefan, Raimbourg Judith, Daniel Catherine, Janicot Henri, Madroszyk Anne, Audigier-Valette Clarisse, Quoix Elisabeth, Mazieres Julien, Moro-Sibilot Denis, Dansin Eric, Molinier Olivier, Morel Hugues, Pichon Eric, Cortot Alexis, Otto Josiane, Chomy François, Souquet Pierre-Jean, Cloarec Nicolas, Giroux-Leprieur Etienne, Bieche Ivan, Lacroix Ludovic, Boyault Sandrine, Attignon Valery, Soubeyran Isabelle, Morel Alain, Tran-Dien Alicia, Jacquet Alexandra, Dall'Olio Filippo Gustavo, Jimenez Marta, Soria Jean-Charles, Besse Benjamin

Abstract excerpt

PURPOSE: Targeted therapies (TT) and immune checkpoint blockers (ICB) have revolutionized the approach to non-small cell lung cancer (NSCLC) treatment in the era of precision medicine. Their impact as switch maintenance therapy based on molecular characterization is unknown. PATIENTS AND METHODS: SAFIR02-Lung/IFCT 1301 was an open-label, randomized, phase II trial, involving 33 centers in France. We investigated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to B7-H1 Antigen

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Precision Medicine

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed

Identifiers

PMID: 35802649
DOI: 10.1158/1078-0432.CCR-22-0371

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial.PMID 35802649Read ↗

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.Semantic proximity Read ↗

Paradigm shift in the management of metastatic Non-small Cell Lung CancerSemantic proximity Read ↗

Precision medicine in non-small cell lung cancer: Current applications and future directions.Semantic proximity Read ↗

Precision treatment for metastatic non-small cell lung cancer: A conceptual overview.Semantic proximity Read ↗

Real-World Survival Outcomes in Non-Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country.Semantic proximity Read ↗

The evolving paradigm of precision medicine in lung cancer.Semantic proximity Read ↗

Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non–Small-Cell Lung Cancer With Rare or Complex Mutational ProfilesSemantic proximity Read ↗

Innovative Clinical Trials: The LUNG-MAP Study.Semantic proximity Read ↗

Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung CancerSemantic proximity Read ↗

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.Semantic proximity Read ↗

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung CancerSemantic proximity Read ↗

Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival OutcomesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.